NCT04929548View on ClinicalTrials.gov

Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

January 5, 2022

Study Completion Date

September 20, 2027

Conditions

Breast Cancer

Interventions

DRUG

Pyrotinib Maleate Tablets

Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.

All Listed Sponsors

lead

Wuhan University

OTHER